KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EBT: 2009-2025

Historic EBT for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $646.0 million.

  • Teva Pharmaceutical Industries' EBT rose 299.38% to $646.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $896.0 million, marking a year-over-year increase of 148.22%. This contributed to the annual value of -$1.3 billion for FY2024, which is 105.77% down from last year.
  • According to the latest figures from Q3 2025, Teva Pharmaceutical Industries' EBT is $646.0 million, which was up 218.23% from $203.0 million recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' EBT registered a high of $646.0 million during Q3 2025, and its lowest value of -$1.8 billion during Q4 2023.
  • Moreover, its 3-year median value for EBT was -$246.0 million (2024), whereas its average is -$190.3 million.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 703.92% in 2021, then plummeted by 774.31% in 2022.
  • Over the past 5 years, Teva Pharmaceutical Industries' EBT (Quarterly) stood at -$175.0 million in 2021, then plummeted by 577.14% to -$1.2 billion in 2022, then plummeted by 48.10% to -$1.8 billion in 2023, then soared by 85.93% to -$247.0 million in 2024, then skyrocketed by 299.38% to $646.0 million in 2025.
  • Its EBT was $646.0 million in Q3 2025, compared to $203.0 million in Q2 2025 and $294.0 million in Q1 2025.